Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nadecnemab
- Development stage
- Discontinued
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Nadecnemab is a human IgG4κ monoclonal antibody developed by Regeneron Pharmaceuticals. It functions as an antagonist of glial cell line-derived neurotrophic factor family receptor alpha-3 (GFRα3). The drug was investigated for its potential in treating chronic pain conditions, particularly osteoarthritis (OA) knee pain, by targeting the artemin-GFRα3 signaling pathway, which has been implicated in various painful conditions. While Nadecnemab demonstrated safety comparable to placebo in a Phase 1 study in healthy volunteers, a subsequent Phase 2 study in patients with OA knee pain failed to meet its primary and secondary efficacy endpoints.
- Other names
- Anti-GFRA3 AntibodyAnti-GFRA-3 AntibodyAnti-GFRA 3 Antibody
02
Targets
GFRA3 (GDNF family receptor alpha-3)
Beyond the preview
Go deeper on Nadecnemab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nadecnemab.